Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) (DIOPSYS-ND)
Primary Purpose
Glaucoma
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Diopsys NOVA
Sponsored by
About this trial
This is an interventional diagnostic trial for Glaucoma focused on measuring Pattern Electroretinogram (PERG), Flash Electroretinogram (FERG)
Eligibility Criteria
Inclusion Criteria:
- Healthy volunteers age 18 years
- older with normal eye exam
Exclusion Criteria:
- spherical refraction outside + 5.0 Diopters and cylinder correction outside + 3.0 Diopters.
- IOP (intraocular pressure) ≥ 22 mm Hg (millimeters of mercury)
- history of any type of glaucoma in either eye.
- Intraocular surgery in study eye (except non-complicated cataract or refractive surgery performed more than 1 year before enrollment).
- Best corrected visual acuity worse than 20/40.
- Evidence of diabetic retinopathy, diabetic macular edema, or other vitreo-retinal disease in either eye.
- Evidence of optic nerve, macula and/or retinal nerve fiber layer abnormality in either eye.
- Evidence of reproducible (false positives, fixation losses and false negatives ≤ 25% with no observable testing artifacts).
- Standard Automatic Perimetry (SAP) abnormality in either eye, defined as Pattern Standard Deviation < 5% level, and/or abnormal Glaucoma Hemifield test result, and/or any other pattern of loss which is consistent with a neurologic and/or ocular disease.
- Current or recent (within the past 30 days) use of an agent (by any administering method) known to affect visual function.
- Inability to obtain reliable PERG/FERG (Pattern Electroretinogram/Flash Electroretinogram) results.
Sites / Locations
- Wills Eye Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Healthy Controls
Arm Description
Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
Outcomes
Primary Outcome Measures
Flash Electroretinogram (FERG) Module Using Diopsys NOVA (Neuro Optic Vision Assessment) Amplitude
Clinical data from participants with a normal eye examination to establish expected normal values of Flash Electroretinogram (FERG) photopic negative response (PhNR) amplitude in micro volts.
Flash Electroretinogram (FERG) Module Using Diopsys NOVA Latency
Clinical data from participants with a normal eye examination to establish expected normal values of Flash Electroretinogram (FERG) photopic negative response (PhNR) latency in milliseconds.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02609204
Brief Title
Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)
Acronym
DIOPSYS-ND
Official Title
NOVA™ PERG (Pattern Electroretinogram)and FERG (Flash Electroretinogram): Establishment of Reference Values for PERG and FERG Measurements
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Wills Eye
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main goal of the study is to compile a normative database for the Neuro Optic Vision Assessment (NOVATM) Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules. This normalization intends to be included in a probabilistic analysis protocol to allow NOVATM PERG/FERG users to identify patients with results outside the normal ranges.
Detailed Description
Investigators plan to enroll 50 subjects at Wills Eye Hospital without any eye diseases.
Participants will undergo a complete eye examination to determine eligibility, including visual acuity testing, intraocular pressure (IOP) in millimeters of mercury (mmHG), and visual field (VF) testing.
Participants will then be tested with Diopsys NOVA™ PERG & FERG systems. For both tests, two electrodes are placed on the skin underneath each eye below the eyelashes. Participants' skin will be cleaned before electrodes are placed. A small amount of gel will be placed on skin where electrodes are placed for testing. Electrical responses are recorded with electrodes in response to visual stimuli.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
Keywords
Pattern Electroretinogram (PERG), Flash Electroretinogram (FERG)
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
51 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Healthy Controls
Arm Type
Experimental
Arm Description
Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
Intervention Type
Diagnostic Test
Intervention Name(s)
Diopsys NOVA
Other Intervention Name(s)
Diopsys-ND
Intervention Description
Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
Primary Outcome Measure Information:
Title
Flash Electroretinogram (FERG) Module Using Diopsys NOVA (Neuro Optic Vision Assessment) Amplitude
Description
Clinical data from participants with a normal eye examination to establish expected normal values of Flash Electroretinogram (FERG) photopic negative response (PhNR) amplitude in micro volts.
Time Frame
2 hours
Title
Flash Electroretinogram (FERG) Module Using Diopsys NOVA Latency
Description
Clinical data from participants with a normal eye examination to establish expected normal values of Flash Electroretinogram (FERG) photopic negative response (PhNR) latency in milliseconds.
Time Frame
2 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers age 18 years
older with normal eye exam
Exclusion Criteria:
spherical refraction outside + 5.0 Diopters and cylinder correction outside + 3.0 Diopters.
IOP (intraocular pressure) ≥ 22 mm Hg (millimeters of mercury)
history of any type of glaucoma in either eye.
Intraocular surgery in study eye (except non-complicated cataract or refractive surgery performed more than 1 year before enrollment).
Best corrected visual acuity worse than 20/40.
Evidence of diabetic retinopathy, diabetic macular edema, or other vitreo-retinal disease in either eye.
Evidence of optic nerve, macula and/or retinal nerve fiber layer abnormality in either eye.
Evidence of reproducible (false positives, fixation losses and false negatives ≤ 25% with no observable testing artifacts).
Standard Automatic Perimetry (SAP) abnormality in either eye, defined as Pattern Standard Deviation < 5% level, and/or abnormal Glaucoma Hemifield test result, and/or any other pattern of loss which is consistent with a neurologic and/or ocular disease.
Current or recent (within the past 30 days) use of an agent (by any administering method) known to affect visual function.
Inability to obtain reliable PERG/FERG (Pattern Electroretinogram/Flash Electroretinogram) results.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
L. Jay Katz, MD
Organizational Affiliation
Wills Eye Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wills Eye Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)
We'll reach out to this number within 24 hrs